191.022 articles found

What happens to microglial TREM2 in Alzheimer's disease: Immunoregulatory turned into immunopathogenic?

Lue LF, Schmitz C, Walker DG.

Neuroscience · 2014-10-02

DOI: 10.1016/j.neuroscience.2014.09.050PMID: 25281879

The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Schapansky J, Nardozzi JD, LaVoie MJ.

Neuroscience · 2014-10-02

DOI: 10.1016/j.neuroscience.2014.09.049PMID: 25284317

Dynamics of postural control in Parkinson patients with and without symptoms of freezing of gait.

Pelykh O, Klein AM, Bötzel K, Kosutzka Z, Ilmberger J.

Gait Posture · 2014-10-02

DOI: 10.1016/j.gaitpost.2014.09.021PMID: 26164353

Therapeutic stromal nanoparticles for Parkinson’s disease

Check source for author details

Disease models & mechanisms · 2014-10-01

P24. Epidemiologic, clinical characteristics of elderly non-small lung cancer patients treated in a single institution

Check source for author details

Translational Lung Cancer Research · 2014-10-01

Willingness to pay for a new drug delivery in Parkinson patients.

Lökk J, Olofsson S, Persson U.

J Multidiscip Healthc · 2014-10-01

DOI: 10.2147/jmdh.s67929PMID: 25336962

PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model.

Youn JK, Kim DW, Kim ST, Park SY, Yeo EJ, Choi YJ, Lee HR, Kim DS, Cho SW, Han KH, Park J, Eum WS, Hwang HS, Choi SY.

BMB Rep · 2014-10-01

DOI: 10.5483/bmbrep.2014.47.10.286PMID: 24499676

P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases.

Pieper AA, McKnight SL, Ready JM.

Chem Soc Rev · 2014-10-01

DOI: 10.1039/c3cs60448aPMID: 24514864

PET/SPECT imaging agents for neurodegenerative diseases.

Zhu L, Ploessl K, Kung HF.

Chem Soc Rev · 2014-10-01

DOI: 10.1039/c3cs60430fPMID: 24676152

Post-dengue encephalopathy and Parkinsonism.

Fong CY, Hlaing CS, Tay CG, Ong LC.

Pediatr Infect Dis J · 2014-10-01

DOI: 10.1097/inf.0000000000000382PMID: 24776518

Validation of FreeSurfer-estimated brain cortical thickness: comparison with histologic measurements.

Cardinale F, Chinnici G, Bramerio M, Mai R, Sartori I, Cossu M, Lo Russo G, Castana L, Colombo N, Caborni C, De Momi E, Ferrigno G.

Neuroinformatics · 2014-10-01

DOI: 10.1007/s12021-014-9229-2PMID: 24789776

The neurotoxicity of 5-S-cysteinyldopamine is mediated by the early activation of ERK1/2 followed by the subsequent activation of ASK1/JNK1/2 pro-apoptotic signalling.

Vauzour D, Pinto JT, Cooper AJ, Spencer JP.

Biochem J · 2014-10-01

DOI: 10.1042/bj20131519PMID: 24938188